Houston-based Dr. Theodoros Voloyiannis was one of six involved in a remote surgery in space demonstration. Photo courtesy of Texas Oncology

A small surgical robot at the International Space Station completed its first surgery demo in zero gravity last week, and one of the surgeons tasked with the remote robotic operations on simulated tissue was Houston-based Dr. Theodoros Voloyiannis.

Voloyiannis took part in what is being referred to as “surgery in space” by being one of the six doctors remotely controlling spaceMIRA — Miniaturized In Vivo Robotic Assistant — that performed several operations on simulated tissue at the lab located in the space station. The surgeons operated remotely from earth in Lincoln, Nebraska. The remote surgeons worked to control the robot's hands to provide tension to the simulated tissue made of rubber bands. They then used the other hand to dissect the elastic tissue with scissors.

“I said during the procedure ‘it was a small rubber band cut, but a great leap for surgery,’“ Voloyiannis tells InnovationMap. “This was a huge milestone for me personally in my career.”

The robot was developed by Virtual Incision Corporation, and made possible through a partnership between NASA and the University of Nebraska. The team of surgeons took part in a demonstration that is considered a common surgical task, as they dissected the correct piece of tissue under pressure.

Latency is the time delay between when the command is sent and the robot receives it, and that was the big challenge the team faced. The delay was about 0.85 of a second according to what the colorectal surgeon who worked on spaceMIRA Dr. Michael Jobst said to CNN. The demo overall was a success according to the team, and posed a new-found adrenaline rush due to the groundbreaking innovation.

“The excitement of the new and the unknown,” Voloyiannis says on the feeling of doing the first operation of its kind. “I never thought I’d be doing something like this when I was in training and in medical school.”

Voloyiannis serves as the chairman of colon and rectal surgery for The US Oncology Network. He was chosen for this experiment due to his experience and expertise performing robotic colorectal surgery. Voloyiannis and the developers are hopeful that this type of technology will soon allow doctors to perform this specialized robotic surgery on patients living in rural areas without a specialized surgeon nearby, military battlefields, as well as regularly in space one day.

“The same concept of remote surgery regularly in space could certainly be entertained,” Voloyiannis says. “When you do things with an absence of gravity and perform a surgery in that environment — of course that changes the way we do things. When you have an absence of gravity with bodily fluids, it is a very hard surgery, but with partial gravity that idea can be entertained.

"Remotely, internet connectivity would have to be considered and you’d have someone remote like me here, while potentially there you’d have someone with less training doing the procedure there guiding the robot," he continues. "It’s quite the concept though.”

The doctors had to account for nearly a second of delay in connectivity. Photo courtesy of Texas Oncology

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.